Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.
The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.
For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.
Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.
Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.